Comparative Pharmacology
Head-to-head clinical analysis: DILOR 400 versus THEOVENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILOR 400 versus THEOVENT.
DILOR-400 vs THEOVENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase inhibitor; inhibits PDE4 and PDE5, leading to increased intracellular cAMP and cGMP, resulting in bronchodilation and vasodilation.
Theovent is a brand name for theophylline, a xanthine derivative that acts as a bronchodilator by inhibiting phosphodiesterase, leading to increased intracellular cAMP levels, and by antagonizing adenosine receptors.
400 mg orally every 6 to 8 hours; maximum daily dose 2400 mg.
Oral: 200-400 mg every 12 hours; maximum 800 mg/day. Intravenous: 200 mg loading dose over 30 minutes, then 200 mg every 12 hours.
None Documented
None Documented
3.1 hours (terminal elimination half-life; may increase in hepatic impairment or congestive heart failure)
Terminal elimination half-life 7-9 hours, prolonged in patients with hepatic impairment (up to 12 hours) or heart failure.
Renal (70% unchanged), hepatic metabolism (30%)
Renal (70% as unchanged drug), biliary/fecal (30% as metabolites).
Category C
Category C
Bronchodilator
Bronchodilator